<DOC>
	<DOCNO>NCT01064375</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity CEA DNA immunisation approach patient colorectal cancer . The DNA plasmid , tetwtCEA , encode wild type human CEA fuse tetanus toxoid T helper epitope . The vaccine deliver use intradermal electroporation device , Derma Vax ( Cyto Pulse Sciences ) . The follow assess : - The efficiency prim immunological response CEA intradermal administration CEA DNA combination electroporation . - The efficiency boost immunological response CEA intradermal administration CEA DNA combination electroporation subject already vaccinate CEA DNA . - GM-CSF administered half subject prim CEA DNA combination electroporation possible adjuvant effect GM-CSF evaluate .</brief_summary>
	<brief_title>Safety Study DNA Vaccine Delivered Intradermal Electroporation Treat Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histological confirm AJCC stage II III colorectal cancer Resection primary tumour without evidence remain macroscopic disease Allowable standard chemotherapy radiotherapy AJCC stage III complete minimum 2 month prior study entry Patients recruit vaccination CEA66 plasmid DNA must complete trial 18 month immune response proven proven nonimmune responder two consecutive immunoassay . Age &gt; 18 year Karnofsky performance &gt; 80 % Life expectancy great 6 month Normal organ marrow function Normal thyroid function measure serum T3 , T4 TSH Normal echocardiogram regard arrhythmia ( chronic treat atrial fibrillation allow ) No concurrent treatment ( chemotherapy biological ) may plan protocol treatment Women men reproductive potential must agree use adequate contraception prior study entry 3 month last injection Ability understand willingness sign inform consent document Immunotherapy systemic corticosteroid within 8 week prior enter study Chemotherapy radiotherapy within 2 month prior enter study Known hypersensitivity GMCSF Previous splenectomy radiation therapy spleen Pregnancy nursing HIV seropositivity Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic intracranial disease , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement History severe neurological , cardiovascular , renal , hepatic , respiratory , bone marrow dysfunction , organ graft autoimmune disease ( treat ) Concomitant medication anticoagulant ( acetylsalicylic acid lowmolecular weight heparin prophylactic dose allow ) Other malignancy , except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year Cardiac demand pacemaker surgically implanted defibrillator . Patients metal implant area injection , ( e.g . shoulder implant upper arm shoulder girdle )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>DNA vaccine</keyword>
	<keyword>Electroporation</keyword>
</DOC>